Compare Kalypsys vs Transposagen Biopharmaceuticals
Customers evaluate the quality of Kalypsys's products using the following success metrics.
Overview
Kalypsys is 23 yrs old and is based in United States.
Kalypsys is a drug discovery company using a cellular ultra high-throughput system to carry out massive drug screening in cellular models of human disease and toxicology.
Transposagen Biopharmaceuticals is 21 yrs old and is based in United States.
Transposagen Biopharmaceuticals is a biotechnology company. It develops and provides early gene editing technology for disease modeling, bioproduction, and phenotypic screening. The company serves the research needs of both academic and drug discovery investigators. It was founded in 2003 and is based in Lexington, Kentucky.
Demo Video
Leadership
Jeremy S. Caldwell (Founder)
Jack Crawford (Chief Executive Officer)
Funding
Investors
Presidio Partners, Tavistock Group
National Institutes of Health, Small Business Innovation Research Awards
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because Kalypsys has not claimed their profile.
Work for Kalypsys? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Kalypsys?
Claim your profile now.
Information not available because Transposagen Biopharmaceuticals has not claimed their profile.
Work for Transposagen Biopharmaceuticals? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Transposagen Biopharmaceuticals?
Claim your profile now.
Expert Collections
Digital Health
10,565 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.